Literature DB >> 17259870

The efficacy of influenza vaccine for healthy children: a meta-analysis evaluating potential sources of variation in efficacy estimates including study quality.

Lamberto Manzoli1, Francesco Schioppa, Antonio Boccia, Paolo Villari.   

Abstract

BACKGROUND: Two systematic reviews evaluating influenza vaccine efficacy in healthy children have recently been published. Although quantitative summary estimates were similar, authors' conclusions were quite contrasting. We carried out another meta-analysis reevaluating study inclusion criteria and using metaregression techniques in addition to sensitivity and subgroups analyses to evaluate potential sources of heterogeneity of efficacy estimates, including methodologic quality of studies.
METHODS: Only randomized clinical studies assessing the efficacy of influenza vaccine in healthy children/adolescents (age < or =18 years) for preventing naturally occurring influenza and/or acute otitis media cases were included. Summary estimates of effect were obtained using a random effects model. The methodologic quality of each study was assessed using 3 systems: Chalmers scale, Jadad scale and Schulz components (randomization, allocation concealment and double-blinding).
RESULTS: The overall vaccination efficacy was 36% (95% confidence interval: 31-40%) against clinically diagnosed illnesses (evaluated by 19 randomized clinical studies for a total of 247,517 children); 67% (51-78%) against laboratory-confirmed cases (18 trials, n = 8574); and 51% (21-70%) against acute otitis media (11 trials, n = 11,349). Significant sources of between-study heterogeneity were participants' age and study quality both directly correlated with the efficacy. When the analysis was performed excluding USSR studies, the overall efficacy of the vaccine in preventing clinical cases substantially increased (from 36% to 61%).
CONCLUSIONS: These findings may indicate that the vaccine efficacy might be greater than the overall estimates. Although no safety and cost considerations are addressed in this analysis, the present findings support vaccination as a possible option for the prevention of influenza in healthy children and adolescents.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17259870     DOI: 10.1097/01.inf.0000253053.01151.bd

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  40 in total

Review 1.  Influenza vaccines: from surveillance through production to protection.

Authors:  Pritish K Tosh; Robert M Jacobson; Gregory A Poland
Journal:  Mayo Clin Proc       Date:  2010-01-29       Impact factor: 7.616

2.  Protective Efficacy of the Conserved NP, PB1, and M1 Proteins as Immunogens in DNA- and Vaccinia Virus-Based Universal Influenza A Virus Vaccines in Mice.

Authors:  Wenling Wang; Renqing Li; Yao Deng; Ning Lu; Hong Chen; Xin Meng; Wen Wang; Xiuping Wang; Kexia Yan; Xiangrong Qi; Xiangmin Zhang; Wei Xin; Zhenhua Lu; Xueren Li; Tao Bian; Yingying Gao; Wenjie Tan; Li Ruan
Journal:  Clin Vaccine Immunol       Date:  2015-04-01

Review 3.  Vaccination greatly reduces disease, disability, death and inequity worldwide.

Authors:  F E Andre; R Booy; H L Bock; J Clemens; S K Datta; T J John; B W Lee; S Lolekha; H Peltola; T A Ruff; M Santosham; H J Schmitt
Journal:  Bull World Health Organ       Date:  2008-02       Impact factor: 9.408

4.  Toward effective vaccine deployment: a systematic study.

Authors:  Jiming Liu; Shang Xia
Journal:  J Med Syst       Date:  2011-05-24       Impact factor: 4.460

5.  Reducing inappropriate antibiotic use among children with influenza infection.

Authors:  Bat-Chen Friedman; Derek Schwabe-Warf; Ran Goldman
Journal:  Can Fam Physician       Date:  2011-01       Impact factor: 3.275

6.  [The universal influenza vaccination in children with Vaxigrip Tetra® in Italy: an evaluation of Health Technology Assessment].

Authors:  Sara Boccalini; Angela Bechini; Maddalena Innocenti; Gino Sartor; Federico Manzi; Paolo Bonanni; Donatella Panatto; Piero Luigi Lai; Francesca Zangrillo; Emanuela Rizzitelli; Mariasilvia Iovine; Daniela Amicizia; Chiara Bini; Andrea Marcellusi; Francesco Saverio Mennini; Alessandro Rinaldi; Francesca Trippi; Anna Maria Ferriero; Giovanni Checcucci Lisi
Journal:  J Prev Med Hyg       Date:  2018-05-30

7.  An inactivated, adjuvanted whole virion clade 2.2 H5N1 (A/Chicken/Astana/6/05) influenza vaccine is safe and immunogenic in a single dose in humans.

Authors:  Abylay R Sansyzbay; Marianna K Erofeeva; Berik M Khairullin; Nurlan T Sandybayev; Zhailaubay K Kydyrbayev; Seidigapbar M Mamadaliyev; Markhabat M Kassenov; Maria V Sergeeva; Julia R Romanova; Vera Z Krivitskaya; Oleg I Kiselev; Marina A Stukova
Journal:  Clin Vaccine Immunol       Date:  2013-06-26

8.  Optimal pandemic influenza vaccine allocation strategies for the Canadian population.

Authors:  Ashleigh R Tuite; David N Fisman; Jeffrey C Kwong; Amy L Greer
Journal:  PLoS One       Date:  2010-05-06       Impact factor: 3.240

Review 9.  Central European Vaccination Advisory Group (CEVAG) guidance statement on recommendations for influenza vaccination in children.

Authors:  Vytautas Usonis; Ioana Anca; Francis André; Roman Chlibek; Inga Ivaskeviciene; Atanas Mangarov; Zsófia Mészner; Roman Prymula; Pavol Simurka; Eda Tamm; Goran Tesović
Journal:  BMC Infect Dis       Date:  2010-06-14       Impact factor: 3.090

10.  Optimal pandemic influenza vaccine allocation strategies for the canadian population.

Authors:  Ashleigh Tuite; David N Fisman; Jeffrey C Kwong; Amy Greer
Journal:  PLoS Curr       Date:  2010-01-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.